Less Is More: GLP-1 Drugs Keep Working at Lower Doses as the World Scrambles to Regulate Them

You don't need the full punch to feel the effect. New research published in Biology Methods & Protocols found that patients who stayed on the lowest starting doses of GLP-1 drugs — tirzepatide (Zepbound) and semaglutide (Wegovy) — for a full year still lost meaningful weight: 5.5% of body weight on sustained low-dose tirzepatide and 2.2% on sustained low-dose semaglutide. The trade-off? More modest losses than the full-dose titration path, but...